SE504675C2 - Ligander för att öka B-Cell-Proliferation - Google Patents

Ligander för att öka B-Cell-Proliferation

Info

Publication number
SE504675C2
SE504675C2 SE8702463A SE8702463A SE504675C2 SE 504675 C2 SE504675 C2 SE 504675C2 SE 8702463 A SE8702463 A SE 8702463A SE 8702463 A SE8702463 A SE 8702463A SE 504675 C2 SE504675 C2 SE 504675C2
Authority
SE
Sweden
Prior art keywords
cells
cell
bcgf
proliferation
bp5o
Prior art date
Application number
SE8702463A
Other languages
English (en)
Swedish (sv)
Other versions
SE8702463L (sv
SE8702463D0 (sv
Inventor
Jeffrey A Ledbetter
Edward A Clark
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Publication of SE8702463D0 publication Critical patent/SE8702463D0/xx
Publication of SE8702463L publication Critical patent/SE8702463L/
Publication of SE504675C2 publication Critical patent/SE504675C2/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SE8702463A 1986-06-13 1987-06-12 Ligander för att öka B-Cell-Proliferation SE504675C2 (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87388486A 1986-06-13 1986-06-13

Publications (3)

Publication Number Publication Date
SE8702463D0 SE8702463D0 (sv) 1987-06-12
SE8702463L SE8702463L (sv) 1987-12-14
SE504675C2 true SE504675C2 (sv) 1997-04-07

Family

ID=25362524

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8702463A SE504675C2 (sv) 1986-06-13 1987-06-12 Ligander för att öka B-Cell-Proliferation

Country Status (22)

Country Link
JP (1) JPH0762040B2 (nl)
KR (1) KR910004100B1 (nl)
AT (1) AT398437B (nl)
AU (1) AU617087B2 (nl)
BE (1) BE1000587A4 (nl)
CA (1) CA1338781C (nl)
CH (1) CH676600A5 (nl)
CY (1) CY1681A (nl)
DE (1) DE3719398C2 (nl)
DK (1) DK173940B1 (nl)
FR (1) FR2607136B1 (nl)
GB (1) GB2191494B (nl)
GR (1) GR870930B (nl)
HK (1) HK10293A (nl)
IE (1) IE60486B1 (nl)
IL (1) IL82841A (nl)
IT (1) IT1208649B (nl)
LU (1) LU86919A1 (nl)
NL (1) NL195022C (nl)
PT (1) PT85073B (nl)
SE (1) SE504675C2 (nl)
SG (1) SG118992G (nl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
CO4600681A1 (es) * 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443427A (en) * 1982-06-21 1984-04-17 Sidney Farber Cancer Institute, Inc. Monoclonal antibody
EP0117705A3 (en) * 1983-02-24 1985-09-25 The Regents Of The University Of California Monoclonal antibody specific for monocytes and blast cells
FR2547731A1 (fr) * 1983-06-27 1984-12-28 Centre Nat Rech Scient Immunotoxine antitumorale, preparations pharmaceutiques la contenant et son utilisation in vitro
US4585742A (en) * 1983-12-14 1986-04-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibody with specificity to human small cell carcinoma and use thereof

Also Published As

Publication number Publication date
IE871563L (en) 1987-12-13
BE1000587A4 (fr) 1989-02-14
PT85073A (en) 1987-07-01
FR2607136B1 (fr) 1989-09-15
IL82841A0 (en) 1987-12-20
GB8713650D0 (en) 1987-07-15
NL195022C (nl) 2003-06-18
CY1681A (en) 1993-10-10
DK302287D0 (da) 1987-06-12
JPH0762040B2 (ja) 1995-07-05
CA1338781C (en) 1996-12-10
DE3719398C2 (de) 1996-03-28
AU617087B2 (en) 1991-11-21
SE8702463L (sv) 1987-12-14
JPS6480299A (en) 1989-03-27
AU7421487A (en) 1987-12-17
IT8720899A0 (it) 1987-06-12
NL8701371A (nl) 1988-01-04
LU86919A1 (fr) 1989-03-08
DE3719398A1 (de) 1988-01-28
KR910004100B1 (ko) 1991-06-22
SG118992G (en) 1993-01-29
IE60486B1 (en) 1994-07-27
GB2191494A (en) 1987-12-16
IL82841A (en) 1992-11-15
AT398437B (de) 1994-12-27
GB2191494B (en) 1990-08-22
IT1208649B (it) 1989-07-10
KR880000582A (ko) 1988-03-28
GR870930B (en) 1987-12-16
PT85073B (pt) 1990-07-31
SE8702463D0 (sv) 1987-06-12
CH676600A5 (nl) 1991-02-15
HK10293A (en) 1993-02-19
DK173940B1 (da) 2002-03-04
ATA151387A (de) 1994-04-15
FR2607136A1 (fr) 1988-05-27
DK302287A (da) 1987-12-14

Similar Documents

Publication Publication Date Title
US5182368A (en) Ligands and methods for augmenting B-cell proliferation
US5786456A (en) Bp 50-specific antibodies and fragments thereof
Amlot et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation
Ledbetter et al. Antibodies to common leukocyte antigen p220 influence human T cell proliferation by modifying IL 2 receptor expression.
Clark et al. Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50.
Kirkman et al. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation
Carrera et al. Triggering of co-mitogenic signals in T cell proliferation by anti-LFA-1 (CD18, CD11a), LFA-3, and CD7 monoclonal antibodies.
Ledbetter et al. Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells.
Fleischer A novel pathway of human T cell activation via a 103 kD T cell activation antigen.
ES2249759T3 (es) Anticuerpos monoclonales y fv especificos para antigeno cd2.
Knox et al. Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides
Spertini et al. Induction of human T cell proliferation by a monoclonal antibody to CD5.
Clark et al. Activation of human B cell proliferation through surface Bp35 (CD20) polypeptides or immunoglobulin receptors.
Rigby et al. Comparison of the effects of 1, 25‐dihydroxyvitamin D3 on T lymphocyte subpopulations
US5853721A (en) Antibody to interleukin-12 receptor
GRATAMA et al. Treatment of acute graft-versus-host disease with monoclonal antibody OKT3
Klingbeil et al. Pharmacology and safety assessment of humanized monoclonal antibodies for therapeutic use
SE504675C2 (sv) Ligander för att öka B-Cell-Proliferation
Uckun et al. Leukemic B-cell precursors constitutively express functional receptors for human interleukin-1
Jungi et al. Serum factors, cell membrane CD14, and beta2 integrins are not required for activation of bovine macrophages by lipopolysaccharide
WEIR et al. Evidence that the antiproliferative effect of verapamil on afferent and efferent immune responses is independent of calcium channel inhibition
Kummer et al. In vivo immunosuppression by pan-T cell antibodies relates to their isotype and to their C1q uptake.
AT400956B (de) Verfahren zur gewinnung eines liganden und verfahren zur unterdrückung der proliferation von bp50 exprimierenden zellen
Blazar et al. Effect of recombinant human macrophage colony-stimulating factor in irradiated murine recipients of T-cell-depleted allogeneic or non-depleted syngeneic bone marrow transplants
WO2024081806A2 (en) Heterogeneity of human cd79 and synergistic enhancement of antitumor activity by co-targeting of cd79b and cd79a in the therapy of b cell tumors

Legal Events

Date Code Title Description
NUG Patent has lapsed